PLIANT THERAPEUTICS, INC.

PLRX

PLIANT THERAPEUTICS, INC.

PLRX

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-01-20Shares Purchased (TTM):0Shares Sold (TTM):127,828

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:45,334,241Shares Outstanding:61,803,467Institutional Ownership Pct.:73.35%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	25	22	45	94	87	92	71	80	80	114	63	58
Short Term Investments	133	149	145	148	176	214	285	325	356	368	431	466
Prepaid Expense And Other Assets Current	4	3	4	4	5	6	7	6	11	8	11	11
Accounts Receivable Net Current	-	-	-	-	-	-	-	-	-	-	0	0
Disposal Group Including Discontinued Operation Pr…	1	1	1	-	-	-	0	-	-	-	-	-
Assets Current	163	175	196	246	267	311	362	410	448	490	506	534
Income Taxes Receivable	-	-	-	-	-	-	-	-	-	-	0	0
Property Plant And Equipment Net	2	3	3	4	5	5	6	6	5	6	4	4
Operating Lease Right Of Use Asset	22	23	24	25	26	26	27	28	29	24	1	2
Restricted Cash Noncurrent	1	1	1	1	1	1	1	1	1	1	1	-
Other Assets Noncurrent	1	0	0	0	0	0	0	0	0	0	0	0
Assets	190	203	225	277	300	345	397	446	484	522	512	540
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	0	0	0	1	6	6	7	3	7	5	3
Accrued Liabilities Current	4	4	10	8	7	7	12	10	8	6	10	8
Operating Lease Liability Current	2	2	1	1	1	1	1	0	0	1	1	2
Liabilities Current	16	10	16	18	21	28	33	40	31	30	29	27
Operating Lease Liability Noncurrent	26	27	28	28	29	29	29	30	30	24	0	0
Long Term Debt	0	0	0	30	30	30	30	30	30	30	10	10
Liabilities	43	37	44	76	80	88	93	100	91	84	39	37
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,049	1,045	1,041	1,036	1,030	1,023	1,014	1,005	996	985	973	964
Retained Earnings Accumulated Deficit	-902	-879	-859	-836	-810	-766	-710	-660	-603	-547	-500	-459
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	-0	0	-0	0	0	1	-1	-0	0	-2
Stockholders Equity	147	165	181	200	220	257	304	346	393	437	474	503
Liabilities And Stockholders Equity	190	203	225	277	300	345	397	446	484	522	512	540
Series A Junior Participating Preferred Purchase R…	-	0	-	0	0	0	-	-	-	-	-	-
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	-
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	-
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	-
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	-
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	62	62	61	61	61	61	61	61	60	60	60	60
Shares Outstanding	62	62	61	61	61	61	61	61	60	60	60	60

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-4.17%	-2.50%	-11.67%	-	-	-	-	-	-	-	-	-
2025	-7.53%	-14.38%	7.53%	-2.38%	-9.52%	7.74%	5.23%	-20.92%	-15.03%	1.50%	-9.77%	-5.26%
2024	-12.04%	-22.04%	-3.05%	5.98%	-9.81%	12.84%	-9.15%	-10.73%	-28.11%	6.52%	5.80%	-6.52%
2023	-	-	-	-	-	-	-0.35%	27.54%	20.70%	-14.88%	-27.25%	-11.27%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	9.90	16.89	12.00	13.93	12.99	11.03	10.91	10.26	14.47	16.12	17.72	19.50
Quick Ratio	9.65	16.58	11.73	13.72	12.77	10.84	10.71	10.12	14.12	15.87	17.33	19.12
Working Capital	146.66M	164.57M	180.08M	227.96M	246.85M	282.99M	329.05M	370.08M	416.63M	459.51M	476.98M	506.94M
Leverage & Debt
Debt to Equity	0.29	0.23	0.24	0.38	0.36	0.34	0.31	0.29	0.23	0.19	0.08	0.07
Interest Coverage TTM	-102.50	-67.73	-61.11	-57.14	-66.24	-69.54	-75.52	-88.48	-106.54	-138.79	-145.34	-138.06
Debt Ratio	0.23	0.18	0.20	0.28	0.27	0.25	0.23	0.22	0.19	0.16	0.08	0.07
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Per Share Metrics
Diluted EPS TTM	-1.49	-1.83	-2.43	-2.86	-3.37	-3.59	-3.47	-3.32	-3.07	-2.84	-2.75	-2.60
Free Cash Flow Per Share TTM	-1.63	-1.60	-2.10	-1.79	-1.99	-2.89	-2.63	-2.25	-2.32	-1.97	-2.00	-2.07
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-	-	-78,404.03%	-11,654.75%	-4,922.65%
Net Profit Margin TTM	-	-	-	-	-	-	-	-	-	-68,847.98%	-10,211.14%	-4,380.45%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-97.46%	-83.69%	-63.53%
Net Income Growth (1Y)	-55.41%	-48.42%	-28.99%	-12.98%	11.63%	28.56%	30.35%	29.88%	28.38%	28.60%	30.83%	37.68%
EPS Growth (1Y)	-55.79%	-48.91%	-29.95%	-13.94%	9.80%	26.38%	26.43%	27.65%	25.81%	19.79%	-6.39%	7.95%
Valuation Metrics
P/E TTM	-0.76	-0.69	-0.50	-0.52	-0.34	-0.38	-3.79	-3.38	-3.50	-5.25	-6.59	-6.67
P/B TTM	0.48	0.47	0.41	0.45	0.32	0.32	2.62	1.97	1.65	2.05	2.25	2.06
P/S TTM	-	-	-	-	-	-	-	-	-	3,615.71	673.04	291.96
Market Cap	70.59M	77.87M	74.87M	90.88M	71.21M	82.65M	797.29M	680.79M	649.12M	896.70M	1.06B	1.03B
Enterprise Value	44.22M	54.20M	27.94M	26.11M	13.27M	19.52M	754.83M	629.83M	597.32M	810.92M	1.01B	987.34M
Calculated Values
Free Cash Flow TTM	-100.79M	-99.11M	-129.01M	-109.97M	-122.06M	-176.71M	-159.35M	-136.64M	-139.79M	-118.61M	-117.28M	-123.52M
Net Debt	-26.37M	-23.67M	-46.93M	-64.78M	-57.94M	-63.13M	-42.46M	-50.96M	-51.80M	-85.78M	-54.66M	-47.66M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-01-20Sale

Owner: Coulie, Bernard

Title: President and CEO

Shares: 89,375

Price/Share: $1.28

Value: $114,400.00

Shares Owned: 505,601

Relationship: Director,Officer

Ownership: Direct

2026-01-20Sale

Owner: Kuo, Minnie

Title: Chief Operating Officer

Shares: 6,917

Price/Share: $1.28

Value: $8,853.76

Shares Owned: 37,806

Relationship: Officer

Ownership: Direct

2026-01-20Sale

Owner: Cummings, Keith Lamont

Title: Chief Financial Officer

Shares: 24,002

Price/Share: $1.28

Value: $30,722.56

Shares Owned: 297,214

Relationship: Officer

Ownership: Direct

2026-01-20Sale

Owner: Cheung, Lily

Title: Chief Human Resource Officer

Shares: 7,534

Price/Share: $1.28

Value: $9,643.52

Shares Owned: 44,847

Relationship: Officer

Ownership: Direct

2025-01-22Sale

Owner: Ouimette, Mike

Title: General Counsel & Corp. Sec'y

Shares: 10,230

Price/Share: $10.99

Value: $112,427.70

Shares Owned: 70,544

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-01-20	Coulie, Bernard	Director,Officer	President and CEO	Direct	Sale	89,375	1.28	$114,400.00	505,601	4
2026-01-20	Kuo, Minnie	Officer	Chief Operating Officer	Direct	Sale	6,917	1.28	$8,853.76	37,806	4
2026-01-20	Cummings, Keith Lamont	Officer	Chief Financial Officer	Direct	Sale	24,002	1.28	$30,722.56	297,214	4
2026-01-20	Cheung, Lily	Officer	Chief Human Resource Officer	Direct	Sale	7,534	1.28	$9,643.52	44,847	4
2025-01-22	Ouimette, Mike	Officer	General Counsel & Corp. Sec'y	Direct	Sale	10,230	10.99	$112,427.70	70,544	4
2025-01-17	Cheung, Lily	Officer	Chief Human Resource Officer	Direct	Sale	3,740	11.20	$41,888.00	24,550	4
2025-01-17	Hull, Hans	Officer	Chief Business Officer	Direct	Sale	15,936	11.20	$178,483.20	211,558	4
2025-01-17	Coulie, Bernard	Director,Officer	President and CEO	Direct	Sale	52,419	11.20	$587,092.80	430,517	4
2025-01-17	Lefebvre, Eric	Officer	Chief Medical Officer	Direct	Sale	18,478	11.20	$206,953.60	194,574	4
2025-01-17	Cummings, Keith Lamont	Officer	Chief Financial Officer	Direct	Sale	20,148	11.20	$225,657.60	262,608	4
2024-07-10	Hull, Hans	Officer	Chief Business Officer	Direct	Sale	9,900	11.56	$114,444.00	227,494	4
2024-07-10	Ouimette, Mike	Officer	General Counsel & Corp. Sec'y	Direct	Sale	7,656	11.56	$88,503.36	94,044	4
2024-07-10	Cummings, Keith Lamont	Officer	Chief Financial Officer	Direct	Sale	10,911	11.56	$126,131.16	282,115	4
2024-07-10	Lefebvre, Eric	Officer	Chief Medical Officer	Direct	Sale	12,319	11.56	$142,407.64	213,052	4
2024-07-10	Coulie, Bernard	Director,Officer	President and CEO	Direct	Sale	38,710	11.56	$447,487.60	482,936	4
2024-01-17	Lefebvre, Eric	Officer	Chief Medical Officer	Direct	Sale	10,295	17.23	$177,382.85	156,920	4
2024-01-17	Cummings, Keith Lamont	Officer	Chief Financial Officer	Direct	Sale	9,781	17.23	$168,526.63	194,605	4
2024-01-17	Coulie, Bernard	Director,Officer	President and CEO	Direct	Sale	25,721	17.23	$443,172.83	316,382	4
2024-01-17	Ouimette, Mike	Officer	General Counsel & Corp. Sec'y	Direct	Sale	5,197	17.23	$89,544.31	55,246	4
2024-01-17	Hull, Hans	Officer	Chief Business Officer	Direct	Sale	9,786	17.23	$168,612.78	185,069	4
2023-08-04	Hull, Hans	Officer	Chief Business Officer	Direct	Sale	20,050	20.01	$401,200.50	194,855	4
2023-07-20	Ouimette, Mike	Officer	General Counsel & Corp. Sec'y	Direct	Sale	4,755	17.55	$83,450.25	60,443	4
2023-07-17	Lefebvre, Eric	Officer	Chief Medical Officer	Direct	Sale	22,321	18.01	$402,001.21	167,215	4
2023-07-17	Coulie, Bernard	Director,Officer	President and CEO	Direct	Sale	70,150	18.01	$1,263,401.50	342,103	4
2023-07-17	Hull, Hans	Officer	Chief Business Officer	Direct	Sale	17,937	18.01	$323,045.37	219,183	4
2023-07-17	Ouimette, Mike	Officer	General Counsel & Corp. Sec'y	Direct	Sale	12,778	18.01	$230,131.78	65,198	4
2023-07-17	Cummings, Keith Lamont	Officer	Chief Financial Officer	Direct	Sale	19,771	18.01	$356,075.71	203,999	4
2023-04-03	Ouimette, Mike	Officer	General Counsel & Corp. Sec'y	Direct	Sale	2,877	27.10	$77,966.70	50,789	4
2023-03-30	Coulie, Bernard	Director,Officer	President and CEO	Direct	Sale	35,339	26.52	$937,190.28	274,753	4
2023-03-30	Cummings, Keith Lamont	Officer	Chief Financial Officer	Direct	Sale	9,960	26.52	$264,139.20	148,470	4
2023-03-30	Hull, Hans	Officer	Chief Business Officer	Direct	Sale	9,036	26.52	$239,634.72	201,964	4
2023-03-30	Lefebvre, Eric	Officer	Chief Medical Officer	Direct	Sale	11,245	26.52	$298,217.40	145,786	4
2023-02-03	Coulie, Bernard	Director,Officer	President and CEO	Direct	Sale	15,000	33.72	$505,800.00	240,112	4
2023-02-01	Coulie, Bernard	Director,Officer	President and CEO	Direct	Sale	15,000	34.83	$522,450.00	240,112	4
2023-01-27	Coulie, Bernard	Director,Officer	President and CEO	Direct	Sale	15,000	35.74	$536,100.00	240,112	4
2023-01-25	Coulie, Bernard	Director,Officer	President and CEO	Direct	Sale	15,000	32.84	$492,600.00	93,812	4
2023-01-23	Cummings, Keith Lamont	Officer	Chief Financial Officer	Direct	Sale	30,000	35.00	$1,050,000.00	84,424	4
2023-01-23	Ouimette, Mike	Officer	General Counsel & Corp. Sec'y	Direct	Sale	20,000	34.19	$683,800.00	5,947	4
2023-01-23	Lefebvre, Eric	Officer	Chief Medical Officer	Direct	Sale	67,500	34.48	$2,327,400.00	76,926	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

73.35%

Inst. Shares: 45,334,241

Shares Outstanding: 61,803,467

2025-12-31

70.03%

Inst. Shares: 42,975,990

Shares Outstanding: 61,366,887

2025-09-30

76.73%

Inst. Shares: 47,117,965

Shares Outstanding: 61,406,475

2025-06-30

79.78%

Inst. Shares: 48,974,130

Shares Outstanding: 61,386,183

2025-03-31

90.55%

Inst. Shares: 55,439,888

Shares Outstanding: 61,222,676

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	45,334,241	61,803,467	73.35%
2025-12-31	42,975,990	61,366,887	70.03%
2025-09-30	47,117,965	61,406,475	76.73%
2025-06-30	48,974,130	61,386,183	79.78%
2025-03-31	55,439,888	61,222,676	90.55%
2024-12-31	59,077,514	60,538,639	97.59%
2024-09-30	57,281,121	60,730,935	94.32%
2024-06-30	58,064,950	60,382,796	96.16%
2024-03-31	60,006,603	60,180,921	99.71%
2023-12-31	57,848,993	58,719,083	98.52%
2023-09-30	56,078,243	59,688,451	93.95%
2023-06-30	53,847,101	59,172,869	91.00%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

PLIANT THERAPEUTICS, INC. (PLRX) — SEC Financial Statements & Analysis

PLIANT THERAPEUTICS, INC. (PLRX) is a pharmaceutical preparations company, incorporated in DE. PLIANT THERAPEUTICS, INC. trades on Nasdaq as: PLRX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), PLIANT THERAPEUTICS, INC. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.29x, a Price-to-Sales (P/S) ratio of 3615.71x (TTM), a Price-to-Book (P/B) ratio of 0.48x (TTM), at a market cap of $70.59M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.29x
P/S TTM: 3615.71x
P/B TTM: 0.48x
Market Cap: $70.59M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is PLIANT THERAPEUTICS, INC. in?

PLIANT THERAPEUTICS, INC. (PLRX) operates in the Pharmaceutical Preparations industry.

What is PLRX's market cap?

PLIANT THERAPEUTICS, INC. (PLRX) has a market capitalization of $70.59M as of 2026-06-30.

What exchange does PLRX trade on?

PLIANT THERAPEUTICS, INC. (PLRX) trades on the Nasdaq.

Where is PLIANT THERAPEUTICS, INC. incorporated?

PLIANT THERAPEUTICS, INC. is incorporated in DE.